Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide vaccine group A, C, Y and W-135
- Development stage
- Unknown
- Lead developer
- Bio-Med
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Quadri Meningo is a quadrivalent meningococcal polysaccharide vaccine developed and manufactured by BiO-MeD Private Limited. It is indicated for the active immunization of adults and children against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine is composed of purified capsular polysaccharides from each of these four serogroups. It is typically administered via subcutaneous injection and is used to prevent meningitis and septicaemia in individuals at risk, including travelers to endemic areas and during outbreaks. As a polysaccharide vaccine, it induces a T-cell independent immune response, leading to the production of bactericidal antibodies that facilitate complement-mediated killing of the bacteria.
- Brand names
- Quadri Meningo
- Other names
- Meningococcal Polysaccharide Vaccine (A, C, Y & W135)Quadrivalent Meningococcal Polysaccharide Vaccine
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal polysaccharide vaccine group A, C, Y and W-135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide vaccine group A, C, Y and W-135.